PerkinElmer’s collaboration with the Johns Hopkins University and the University of Birmingham is expected to expand cancer research capabilities by giving key opinion leaders advanced tools, technology and expertise.
“Working in partnership with premier research institutions like Johns Hopkins and the University of Birmingham represents an outstanding opportunity for PerkinElmer to strengthen collaborations with scientific leaders in biomarker discovery and at the same time gather important input on our technologies,” said Robert Friel, president of PerkinElmer life and analytical sciences. “These collaborations further build on our technical expertise, and will hopefully help pave the way to better approaches for the diagnosis and treatment of cancer.”
“Prevention, early detection and specifically targeted therapies through the use of biomarker technology, represent the future in cancer management,” added Dr Philip Johnson, a professor in the division of cancer studies at the University of Birmingham.
These collaborations are expected to become a major driver in the rapidly emerging field of proteomics, developing new technologies for clinical research.